Federal Register / Vol. 89, No. 226 / Friday, November 22, 2024 / Notices 92695 

Office of Resource Access and 

Partnerships, Indian Health Service, 

5600 Fishers Lane, Mail Stop 10E85C, 

Rockville, MD 20857. 

FOR FURTHER INFORMATION CONTACT: 

CAPT John Rael, Director, Office of 

Resource Access and Partnerships by 

email at John.Rael@ihs.gov, or by phone 

at (301) 443–0969 (this is not a toll-free 

number). 

SUPPLEMENTARY INFORMATION: The IHS 

provides services under regulations in 

effect as of September 15, 1987, and 

republished at 42 CFR part 136, 

subparts A–C. Subpart C defines a 

Contract Health Service Delivery Area 

(CHSDA), now referred to as a PRCDA, 

as the geographic area within which 

PRC will be made available by the IHS 

to members of an identified Indian 

community who reside in the PRCDA. 

Residence within a PRCDA by a person 

who is within the scope of the Indian 

health program, as set forth in 42 CFR 

136.12, creates no legal entitlement to 

PRC but only potential eligibility for 

services. Services needed, but not 

available at an IHS/Tribal facility, are 

provided under the PRC program 

depending on the availability of funds, 

the relative medical priority of the 

services to be provided, and the actual 

availability and accessibility of alternate 

resources in accordance with the 

regulations. 

The regulations at 42 CFR part 136, 

subpart C provide that, unless otherwise 

designated, a PRCDA shall consist of a 

county which includes all or part of a 

reservation and any county or counties 

which have a common boundary with 

the reservation. 42 CFR 136.22(a)(6). 

The regulations also provide that after 

Consultation with the Tribal governing 

body or bodies on those reservations 

included within the PRCDA, the 

Secretary may, from time to time, 

redesignate areas within the United 

States for inclusion in or exclusion from 

a PRCDA. 42 CFR 136.22(b). The 

regulations require that certain criteria 

must be considered before any 

redesignation is made. The criteria are 

as follows: 

(1) The number of Indians residing in 

the area proposed to be so included or 

excluded; 

(2) Whether the Tribal governing body 

has determined that Indians residing in 

the area near the reservation are socially 

and economically affiliated with the 

Tribe; 

(3) The geographic proximity to the 

reservation of the area whose inclusion 

or exclusion is being considered; and 

(4) The level of funding which would 

be available for the provision of PRC. 

Additionally, the regulations require 

that any redesignation of a PRCDA be 

made in accordance with the procedures 

of the Administrative Procedure Act 

(5 U.S.C. 553). 42 CFR 136.22(c). In 

compliance with this requirement, the 

IHS published a notice of proposed 

redesignation and requested public 

comments on May 17, 2024 (89 FR 

43415). The IHS did not receive any 

comments in response to the notice of 

proposed redesignation. 

In support of this expansion, the IHS 

makes the following findings: 

1. By expanding the PRCDA to 

include Kalamazoo, Kent, and Ottawa 

Counties in the State of Michigan, the 

Pokagon Band’s PRC-eligible population 

will increase by an estimated 537 Tribal 

citizens. 

2. The Tribal citizens and certain 

other PRC-eligible individuals within 

the expanded PRCDA are socially and 

economically affiliated with the 

Pokagon Band based on a Tribal 

resolution in which the Pokagon Band 

Tribal Council identified its intent to 

expand the PRCDA to include 

Kalamazoo, Kent, and Ottawa Counties 

in Michigan, and stated that the Tribal 

citizens and certain other individuals 

residing in such areas are socially and 

economically affiliated with the 

Pokagon Band. 

3. The expanded PRCDA counties 

form a contiguous area with the existing 

PRCDA, and Pokagon Band citizens 

reside in each of the expansion 

counties. For these reasons, the IHS has 

determined that the expansion counties 

are geographically proximate, meaning 

‘‘on or near’’, to the Pokagon Band’s 

reservation. 

4. The Pokagon Band has indicated 

that its PRC program can continue 

providing the same level of care to the 

expanded PRC-eligible population. No 

additional financial resources will be 

allocated by the IHS to the Pokagon 

Band to provide services to the Pokagon 

Band’s PRC-eligible population as a 

result of this PRCDA expansion. 

An updated listing of the PRCDAs for 

all federally-recognized Tribes may be 

accessed via a link on the IHS PRCDA 

Expansion website (https://

www.ihs.gov/prc/prcda-expansion). 

Public Comments: The IHS did not 

receive any comments in response to the 

notice of proposed expansion. 

Roselyn Tso, 

Director, Indian Health Service. 

[FR Doc. 2024–27457 Filed 11–21–24; 8:45 am] 

BILLING CODE 4166–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Oncology. 

Date: December 17, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Nywana Sizemore, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6189, 

MSC 7804, Bethesda, MD 20892, 301–408– 

9916, sizemoren@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 18, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–27364 Filed 11–21–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 


ddrumheller on DSK120RN23PROD with NOTICES1
92696 Federal Register / Vol. 89, No. 226 / Friday, November 22, 2024 / Notices 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Cell and Gene Therapies for 

HIV Cure: Developing a Pipeline (P01 

Clinical Trial Not Allowed). 

Date: December 16–18, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G11, 

Rockville, MD 20892. 

Contact Person: J. Bruce Sundstrom, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G11, Rockville, MD 

20892, 240–669–5045, sundstromj@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 18, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–27363 Filed 11–21–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the AIDS Research Advisory 

Committee, NIAID. 

The meeting will be held as a virtual 

meeting and will be open to the public 

as indicated below. Individuals who 

plan to view the virtual meeting and 

need special assistance or other 

reasonable accommodations to view the 

meeting should notify the Contact 

Person listed below in advance of the 

meeting. The meeting can be accessed 

from the NIH Videocast at the following 

link: https://videocast.nih.gov/. 

Name of Committee: AIDS Research 

Advisory Committee, NIAID. 

Date: January 27, 2025. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: Report of Division Director and 

Division Staff. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 8D49 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Pamela Gilden, Branch 

Chief, Science Planning and Operations 

Branch, Division of AIDS, National Institute 

of Allergy and Infectious Diseases, National 

Institutes of Health 5601 Fishers Lane, Room 

8D49 Rockville, MD 20852–9831, 301–594– 

9954, pamela.gilden@nih.gov. 

Any interested person may file written 

comments with the committee up to 15 days 

after the meeting date by forwarding the 

statement to the Contact Persons listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Any member of the public interested in 

presenting oral comments to the committee 

must notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to three minutes. Both 

printed and electronic copies are requested 

for the record. 

Information is also available on the 

Institute’s/Center’s home page: https://

www.niaid.nih.gov/about/committees-aidsresearch, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 19, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–27433 Filed 11–21–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Centers for AIDS Research 

(P30 Clinical Trial Not Allowed); 

Developmental Centers for AIDS Research 

(P30 Clinical Trial Not Allowed). 

Date: December 17–18, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G33, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Poonam Pegu, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G33, Rockville, MD 

20892, 240–292–0719, poonam.pegu@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 18, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–27365 Filed 11–21–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Vaccine Research Center 

Board of Scientific Counselors, NIAID. 

The meeting will be open to the 

public via Zoom, https://

nih.zoomgov.com/j/ 

1617772822?pwd=UaZ1sTjftGCftX

jzaWVccw9rIifRg9.1. Individuals who 

plan to attend and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. 

The meeting will be closed to the 

public as indicated below in accordance 


ddrumheller on DSK120RN23PROD with NOTICES1